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Abstract
Epigenetic mechanisms are known to regulate gene expression during chondrogen-
esis. In this study, we have characterized the epigenome during the in vitro differ-
entiation of human mesenchymal stem cells (hMSCs) into chondrocytes. Chromatin 
immunoprecipitation followed by next-generation sequencing (ChIP-seq) was used 
to assess a range of N-terminal posttranscriptional modifications (marks) to his-
tone H3 lysines (H3K4me3, H3K4me1, H3K27ac, H3K27me3, and H3K36me3) 
in both hMSCs and differentiated chondrocytes. Chromatin states were character-
ized using histone ChIP-seq and cis-regulatory elements were identified in chon-
drocytes. Chondrocyte enhancers were associated with chondrogenesis-related gene 
ontology (GO) terms. In silico analysis and integration of DNA methylation data 
with chondrogenesis chromatin states revealed that enhancers marked by histone 
marks H3K4me1 and H3K27ac were de-methylated during in vitro chondrogenesis. 
Similarity analysis between hMSC and chondrocyte chromatin states defined in this 
study with epigenomes of cell-types defined by the Roadmap Epigenomics project 
revealed that enhancers are more distinct between cell-types compared to other chro-
matin states. Motif analysis revealed that the transcription factor SOX9 is enriched 
in chondrocyte enhancers. Luciferase reporter assays confirmed that chondrocyte en-
hancers characterized in this study exhibited enhancer activity which may be modu-
lated by DNA methylation and SOX9 overexpression. Altogether, these integrated 
data illustrate the cross-talk between different epigenetic mechanisms during chon-
drocyte differentiation.
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1 |  INTRODUCTION
Chondrogenesis is the process of differentiation of mesen-
chymal progenitors into chondrocytes. Articular cartilage, 
present in synovial joints, comprises an extracellular matrix 
secreted by chondrocytes and has an important function in 
aiding the mobility of joints. As the only cell type present in 
articular cartilage, adult articular chondrocytes are responsi-
ble for the homeostasis of cartilage.
During embryogenesis, the skeletal system originates 
from the mesoderm germ layer. Mesenchymal progenitors 
differentiate into chondrocytes to form temporary cartilage. 
During endochondral ossification, these cells generally un-
dergo apoptosis to be replaced by bone. However, cartilage 
at synovial joints does not ossify and remains throughout the 
life. Hypertrophic chondrocytes bound for ossification have 
high expression of COL10A1 and osteoblast markers such as 
RUNX2, and low expression of cartilage-specific genes such as 
COL2A1 and SOX9.1,2 Chondrogenesis is a multi-step tightly 
regulated process mediated by growth and transcription factors, 
with the SOX9 transcription factor instrumental to the progres-
sion of chondrogenic differentiation 3 although not initiation.4 
Gene expression during chondrogenesis is in part regulated 
by dynamic epigenetic mechanisms such as DNA methylation 
and histone modifications.5,6 MicroRNAs (miRNAs) and long 
non-coding RNAs (lncRNAs) also play a role in chondrogen-
esis.7-9 Genome-wide histone modification changes have been 
observed during in vitro differentiation of MSCs into chondro-
cytes.10 As well as development, epigenetic mechanisms are 
also known to be involved in disease. Cis-regulatory elements 
such as gene enhancers have been shown to be disrupted in car-
tilage pathologies. Deletions in a distal regulatory region of the 
SOX9 transcription factor gene and within the SOX9 gene itself 
both lead to campomelic dysplasia in humans.11,12 Mutations in 
enhancers of collagen genes are also associated with chondro-
dysplasias.13,14 Osteoarthritis (OA), an age-related cartilage de-
generative disease, has a strong genetic component and to date, 
the vast majority of polymorphisms that confer an increased 
risk are located in non-coding regions of the genome, includ-
ing enhancers.15,16 There is evidence that the OA phenotype 
may be linked to the reactivation of developmental pathways.17 
Articular cartilage affected by OA shows gene expression 
changes reminiscent of hypertrophic chondrocytes.1,18 These 
studies demonstrate that epigenetic mechanisms regulate gene 
expression in numerous biological processes. However, how 
these mechanisms affect gene expression is not fully under-
stood in cartilage development and disease.
Mesenchymal stem cells (MSCs) are able to differentiate 
into chondrocytes and have been used to study chondrogenesis 
in vitro. Tissue engineering solutions to cartilage repair include 
autologous chondrocyte implantation, cartilage autografts, and 
injection of MSCs into the damaged site.19,20 However, these 
methods are not widely used and complications can arise from 
their application. Further knowledge of the regulatory pro-
cesses that control gene expression during chondrocyte devel-
opment is required to develop and improve models for cartilage 
regeneration. Usage of in vitro models for human chondrogen-
esis is crucial for understanding the changes that occur during 
the normal development of human cartilage. Additionally, as 
in vitro models are used extensively for the study of chondro-
genesis, it is important to establish how similar models are to 
each other and to in vivo chondrogenesis.
In this study, histone ChIP-seq (H3K4me3, H3K4me1, 
H3K27ac, H3K27me3, and H3K36me3) was performed in 
a scaffold-free in vitro model of human MSC (hMSC) chon-
drogenesis.21 Analysis of histone ChIP-seq data revealed 
that large scale chromatin state changes occur during chon-
drogenesis and chondrocytes acquire cell-type-specific en-
hancers upon differentiation. Integration of chromatin states 
with genome-wide DNA methylation data demonstrated that 
de-methylated CpG sites are located within H3K27ac and 
H3K4me1 marked enhancers during chondrogenesis. Motif 
analysis revealed that chondrocyte enhancers contain SOX9-
binding motifs. Altogether, our study provides a comprehen-
sive analysis of the global epigenetic changes during MSC 
chondrogenesis and highlights the role of enhancers in defin-
ing cell-type specificity.
2 |  MATERIALS AND METHODS
2.1 | hMSC culture and chondrogenesis
Bone marrow aspirates (donor n = 2, female, ages 22 & 24) 
were purchased from LONZA and hMSCs were isolated by 
adherence to tissue culture flasks for 24 hours. hMSCs were 
phenotyped by flow cytometry22 and confirmed to have os-
teoblastogenic and adipogenetic potential as well as chon-
drogenic. Stem cells were cultured and differentiated into 
chondrocytes as previously described.23
2.2 | Isolation of chondrocytes from 
cartilage-like disc
Cartilage discs were digested at Day 14 of chondrogenesis, 
a time point at which chondrocytes have been determined 
to be fully differentiated in a pellet model of chondrogen-
esis.24 Cartilage discs were digested first with 1.5 mL of 
hyaluronidase (1 mg/mL in sterile PBS) for 15 minutes at 
37°C then with 1.5  mL of trypsin (2.5  mg/mL in sterile 
PBS) at 37°C for 30  minutes. The discs were finally di-
gested with collagenase (2  mg/mL in DMEM media) for 
1-1.5 hours at 37°C until fully digested and the matrix was 
no longer visible. The digested cartilage containing media 
was passed through a 100 μm cell strainer to remove any 
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remaining matrix. Each cartilage disc yielded  ~250,000-
500,000 cells and multiple discs were pooled together dur-
ing extraction.
2.3 | Chromatin extraction and ChIP-seq
hMSCs were harvested from monolayer culture using trypsin. 
Chromatin from hMSCs and differentiated chondrocytes were 
extracted using the Diagenode iDeal histone ChIP-seq kit 
(Diagenode SA, Ougrée, Belgium). Extracted chromatin was 
sonicated using a Diagenode Bioruptor Standard or Bioruptor 
Pico to an average size of 200-500 bp, using 15 sonication cy-
cles (30s on/30  seconds off). ChIP-seq grade premium anti-
bodies were purchased from Diagenode: H3K4me3 (included 
in the Diagenode iDeal histone ChIP-seq kit), H3K4me1 
(Cat. no. C15410194), H3K27ac (Cat. no. C15410196), 
H3K27me3 (Cat. no. C15410195), and H3K36me3 (Cat. no. 
C15410192). Chromatin immunoprecipitation was performed 
following the Diagenode iDeal histone ChIP-seq protocol 
using chromatin from 1 million cells and 1μg antibody per 
ChIP. Immunoprecipitated DNA was purified using Agencourt 
AMPure XP beads (Beckman Coulter (UK) Ltd, High 
Wycombe, UK). For one hMSC chondrogenesis replicate ChIP-
seq, DNA sequencing libraries were generated using Diagenode 
MicroPlex v2 kit and single-ended reads of 50 bp length were 
generated on an Illumina HiSeq 2500 (Illumina Inc, San Diego, 
USA). The second experimental replicate was prepared using 
the NEBNext Ultra II kit (New England Biolabs, Hitchin, UK) 
and sequenced using an Illumina NextSeq 500 platform, gener-
ating 75 bp single-end reads. For both replicates, 30-65 million 
reads were generated per sample (Table S1).
2.4 | Luciferase reporter assays
Putative enhancer regions were amplified from human genomic 
DNA using the primers listed in Table S2 and cloned into the 
pCpGL-EF1 plasmid. This plasmid has been modified from the 
CpG-free pCpGL-basic luciferase plasmid by the addition of 
the EF1 CpG-free promoter upstream of the luciferase gene25 
and can thus be used to analyze DNA methylation effects on 
non-promoter regulatory regions. Plasmids were transformed 
into GT115 E coli (Invitrogen) and DNA isolated using the 
PureYield Plasmid Midiprep system (Promega). Plasmid DNA 
was in vitro methylated using CpG Methyltransferase (M 
SssI, New England Biolabs), with the efficiency of methyla-
tion assessed by digestion using HpaII and HhaI methylation-
sensitive restriction enzymes (NEB). The effect of SOX9 on 
enhancer activity was assessed by transfection with a SOX9 
overexpression plasmid (pUT-FLAG-SOX9).26 A lucif-
erase reporter (4COL) containing four copies of the Col2a1 
48-bp enhancer was used to confirm SOX9 overexpression.27 
SW1353 chondrosarcoma cells were seeded at a cell density of 
5 × 103 per well in 96-well plates. After 24 hours, cells were 
co-transfected with 100 ng (DNA methylation) or 50 ng (SOX9 
overexpression) of the relevant pCpGL-EF1 plasmid and 6ng 
(DNA methylation) or 1.5 ng (SOX9 overexpression) of pRL-
TK Renilla control plasmid and 0.3 μL of FuGENE HD reagent 
(Promega) per well. Cells were lysed 24hrs post-transfection 
and luciferase and the renilla activity measured using the Dual-
Luciferase Reporter Assay kit on a GloMax-Multi reader. 
Three experiments with six replicates each were performed for 
each construct and luciferase/renilla activity normalized to for 
the empty the pCpGL-EF1vector.
2.5 | ChIP-seq analysis and chromatin 
state learning
Quality control of sequencing reads was performed using 
FastQC (v.0.11.5). All reads passed quality thresholds. Reads 
were aligned to the reference human genome hg38 using 
Bowtie2 (v.2.2.4).28 MACS2 (v.2.1.0.2)29 was used to call 
broad peaks (parameters–broad and –no-model) using input 
samples as controls. The ngs.plot program (v.2.61)30 was used 
to visualize peak enrichment across the genome and at gene 
expression levels. An Illumina whole-genome expression 
array Human HT-12 V4 was used to determine gene expres-
sion levels prior and post chondrogenesis.23 Normalized gene 
expression signals were categorized into low (signal < 7; 1st 
quarter), medium (signal between 7 and 9) or high expression 
(signal > 9; 3rd quarter; Table S3).
ChromHMM (v.1.12)31 was used to train a 16 state model 
on all histone marks assayed. The number of states was ar-
rived at by running the model with different numbers of states 
until the separation of chromatin states was seen; as described 
by the Roadmap Epigenomics Project.32 The Integrative 
Genomics Viewer (IGV) was used to visualize chromatin state 
tracks.33 Global chromatin state changes between hMSC and 
differentiated chondrocytes were visualized using the riverplot 
package in R. Gene ontology (GO) terms for chromatin states 
were found using the GREAT tool with default settings.34
Mouse SOX9 ChIP-seq data (GEO GSE69109) were 
aligned to mm10 using Bowtie2 (default settings). Aligned 
reads were converted to hg38 using the UCSC liftOver tool 
and narrow peaks were called using MACS2 (v.2.1.0.2) using 
input samples as control.
2.6 | Chromatin state comparisons with 
roadmap epigenomics cell-types
Chromatin state coordinates from our study were converted to 
hg19 using UCSC liftOver as Roadmap data were aligned to 
hg19. Similarity analysis between equivalent chromatin states 
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across hMSC, chondrocyte, and Roadmap cell-types was per-
formed using the Jaccard index and hierarchical clustering. 
Roadmap chromatin state data are available to download from 
the project website (http://www.roadm apepi genom ics.org/). 
For comparisons with human articular chondrocyte enhancers, 
histone ChIP-seq data from human fetal and adult articular car-
tilage were accessed from GSE11 1850.35
2.7 | Integration with DNA methylation
An Infinium HumanMethylation450 BeadChip array was 
used to quantify DNA methylation in the Transwell model 
of chondrogenesis,36 GEO dataset GSE12 9266. CpG probes 
from the 450K methylation array were based on human 
reference genome hg19; therefore, CpG coordinates from 
the array were first converted to hg38 and intersected with 
chromatin state coordinates from hMSC and differentiated 
chondrocytes. A Chi-square test with 1000 Monte Carlo per-
mutations was used to test the independence of de-methyl-
ated CpG distribution in enhancers. All plots were generated 
using the ggplot2 package in R.
2.8 | Motif analysis
The MEME suite of tools was used for de novo motif search-
ing.37 The analysis of motif enrichment (AME) tool within 
MEME was used to assess the relative enrichment of SOX9-
binding motifs found in the footprintDB database38 in new 
chondrocyte enhancers compared to constant enhancers.
2.9 | Data availability
ChIP-seq data have been deposited GSE12 9031. The chon-
drogenesis 450k DNA methylation array data can be found in 
GSE12 9266. The chondrogenesis transcriptome analysis using 
Illumina whole-genome expression array Human HT-12 V4 is 
available upon reasonable request from the authors.
3 |  RESULTS
3.1 | Chromatin state changes during 
chondrogenesis
Bone marrow-derived hMSCs were differentiated into chon-
drocytes over 14 days using an in vitro Transwell model of 
chondrogenesis. This scaffold-free model produces a carti-
laginous disc which expresses matrix components such as 
type II collagen and sulphated glycosaminoglycans. The pro-
duced matrix assembles cartilage collagens and generates a 
robust collagen network with the prerequisite covalent cross-
links.39 Chondrogenic genes such as SOX9 have been shown 
to be induced during the differentiation of hMSCs using this 
established and reproducible model of chondrogenesis.8,21,23 
We observed the upregulation of markers of articular chon-
drocytes such as COL2A1, TNBS4, PRG4, but also markers 
of hypertrophic chondrocytes such as COL10A1, PTH1R, 
and ALPL (Figure S1).40-42
Histone modifications H3K4me3, H3K4me1, H3K27ac, 
H3K27me3, and H3K36me3 were assayed in hMSCs and dif-
ferentiated chondrocytes (Day 14) using ChIP-seq. These his-
tone marks were selected to reflect a wide range of regulatory 
states. H3K4me3 commonly marks active promoters, H3K4me1 
and H3K27ac are found at active enhancers, H3K36me3 are 
located at actively transcribed regions and H3K27me3 marks 
transcriptionally repressed regions. The genome-wide profiles 
of each histone mark were as expected; the density of each his-
tone mark differs across the genome with the active promoter 
mark H3K4me3 showing a high density of peaks close to tran-
scriptional start sites (TSS; Figure 1A). Histone modifications 
are known to influence gene transcription; therefore, histone 
mark enrichments were correlated with the expression levels 
of genes in hMSCs and differentiated chondrocytes (Figure 1B; 
Table S3). Gene expression in hMSCs and differentiated chon-
drocytes measured by microarray were stratified into groups of 
low, medium, and highly expressed genes (Table S3). Average 
read coverages of histone marks across each group were plot-
ted and as expected histone marks and as expected, histone 
marks typically associated with transcriptional activity were 
enriched in highly expressed genes (Figure 1C). In contrast, the 
transcriptionally repressive mark H3K27me3 showed a greater 
enrichment in genes with low expression levels in differenti-
ated chondrocytes. This demonstrates that the histone ChIP-seq 
generated in hMSCs and differentiated chondrocyte exhibit ex-
pected genome-wide profiles and gene expression associations.
Combinations of histone modifications can reveal more 
information about the regulation of gene expression com-
pared to singular histone marks.43 Regulatory elements and 
chromatin states may be defined by the co-occurrences 
of specific histone marks.44 A 16 chromatin state model 
was trained on the hMSC and differentiated chondrocyte 
ChIP-seq data using ChromHMM (Figure 2A). The model 
yielded a range of chromatin states known to be associ-
ated with the histone modifications assayed in this study 
(model emission probabilities are shown in Table S4). 
This included promoter states, actively transcribed states 
and enhancer elements.32 Large scale changes in chroma-
tin states were observed between hMSCs and differentiated 
chondrocytes, particularly with regards to the quiescent 
and repressed states becoming transcriptionally active 
(Figures 2B, S2), demonstrating that genome-wide histone 
modification changes occur in the epigenome during chon-
drogenesis. To elucidate how chromatin states affect gene 
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expression, the GREAT tool34 was used to retrieve gene 
ontology (GO) terms for each chromatin state. GO terms 
associated with genes linked to each of the defined chroma-
tin states were non-specific to cell-type and mostly encom-
passed general cell functions, the exception being enhancer 
states (Figure S3-S17). In differentiated chondrocytes, the 
strong active enhancer state (characterized by high enrich-
ment of H3K4me1 and H3K27ac; state 13_EnhS) yielded 
GO terms related to chondrogenesis and cartilage function 
(Figure 2C). Previous studies have demonstrated that gene 
enhancers are cell-type specific and play an important role 
in regulating cell-type specific processes.45 Accordingly, 
chondrocyte enhancers defined in this study are associated 
with chondrogenesis related terms, more than promoter 
or gene transcription chromatin states. Chromatin state 
changes can clearly be observed around genes that show 
gene expression changes. For example, we observed the 
histone modification around the COL2A1 gene switching 
from repressed/inactive in hMSCs to transcriptionally per-
missive in chondrocytes (Figure 2D).
3.2 | Comparison to roadmap epigenomics 
cell types
Several large-scale consortia have aimed to characterize the 
epigenomes of various cell-types including the NIH Roadmap 
Epigenomics project,32 which defined chromatin states in 
127 cell-types, 98 of which also included the active en-
hancer mark, H3K27ac. Roadmap cell-types contained bone 
marrow-derived hMSCs and differentiated chondrocytes; 
therefore, we sought to determine whether the epigenome of 
F I G U R E  1  Correlation of histone mark enrichment with gene expression in hMSCs and differentiated chondrocytes. A, Density of histone 
mark peaks around the TSS (±6 kb). Peaks were called using MACS2 using input samples as controls for background noise. B, MA (log ratio—
average expression) plot of differentially expressed genes between hMSCs and differentiated chondrocytes. Gene expression was measured using a 
cDNA microarray and gene expression is reported as normalized signals. Significantly differentially expressed genes are plotted in red. C, Histone 
mark enrichments in genes categorized as high expression (expression value > 9; upper quartile), medium expression (expression value > 7 
and < 9) and low expression (expression value < 7; lower quartile). Histone marks were associated/overlapped to genes using the ngs.plot tool and 
plots were generated in R
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our chondrocytes was comparable to those included in the 
Roadmap project. We compared our 16 chromatin states to 
the equivalent states of the 18 state model generated by the 
Roadmap project for their 98 cell-types that contained the 
H3K27ac active enhancer mark (Figure S18).The Jaccard 
similarity coefficient was used to compare equivalent chro-
matin states across all cell-types in a pairwise manner. When 
individual chromatin states except for enhancers were inves-
tigated there appeared to be no apparent clustering of cells 
by type or origin (Figure S19). In contrast, when H3K27ac 
and H3K4me1 marked enhancers (labeled 13_EnhS in tran-
swell chondrogenesis chromatin state model and 9_EnhA1 
in Roadmap 18 state model) were explored, cells clustered 
with other more closely related cell-types (Figure 3). Our 
differentiated chondrocytes (“CHON” in Figure 3) clustered 
together with the BM-MSC differentiated chondrocytes from 
the Roadmap project,10 demonstrating a higher level of simi-
larity to each other than to all other cell types. The Roadmap 
bone marrow-derived hMSCs and hMSCs in this study were 
closely related, contained within a small cluster of primary 
culture cells consisting of chondrocytes, myocytes, osteo-
blasts, and fibroblasts (Figure 3). These data corroborate pre-
vious studies that report that enhancers are distinct between 
cell-types, more than any other regulatory features such as 
gene promoters.45,46 Further, enhancers in chondrocytes from 
different sources showed higher similarity compared to other 
cell-type enhancers. Thus, there is a chondrocyte-specific epi-
genome based on gene enhancers that can be detected despite 
differences in chondrogenesis models, laboratory, and MSCs 
donors.
3.3 | Comparison to 
chondrocyte epigenomes
Roadmap chondrocyte enhancers were intersected with the 
chondrocyte enhancers identified in this study, resulting in 
a total of 23 158 enhancer regions common to both types of 
MSC-derived chondrocytes (Table S5). We next compared 
these shared in vitro chondrocyte enhancers with enhancers 
F I G U R E  2  A 16 chromatin 
state model generated from hMSC and 
differentiated chondrocyte histone ChIP-seq. 
A, Chromatin state model with annotated 
states. The chromatin state model was 
generated using the ChromHMM tool with 
all hMSC and differentiated chondrocyte 
data using input controls. Intensity of 
blue within the heatmap represents the 
model emission probabilities (Table S4). 
B, Genome-wide changes in chromatin 
states during hMSC chondrogenesis. 
The thickness of the lines represents the 
frequency of chromatin state changes from 
hMSC to chondrocytes (Figure S2). C, 
GREAT biological process GO terms for 
the chondrocyte strong enhancer (13_EnhS) 
state. Genome coordinates of the 13_EnhS 
were used as input into the GREAT tool 
which associates cis-regulatory elements 
with genes. D, IGV genome browser view 
of hMSC and chondrocyte chromatin states 
around the COL2A1 gene. Colors for the 
ChromHMM defined chromatin states are 
as in panel A
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identified in human fetal and adult articular cartilage35 using 
the Jaccard similarity coefficient to assess the concord-
ance. The hMSC-derived chondrocyte enhancer signature 
was more similar to adult articular chondrocytes compared 
to either fetal articular chondrocytes or H1 embryonic stem 
cell-derived chondrocytes (Figure 4A). A study of differen-
tially accessible chromatin regions in matched intact carti-
lage (outer region of the lateral tibial plateau) and damaged 
cartilage (inner region of medial tibial plateau) in OA knee 
found that enhancers were enriched in significantly differen-
tially accessible regions.47 Of the 77 655 enhancers defined 
in the study by Liu et al, 14  954 overlapped with enhanc-
ers found in the shared enhancers in MSC-derived chondro-
cytes. Furthermore, of the 3797 significantly differentially 
accessible enhancers between intact and damaged carti-
lage,47 1239 were also found in differentiated chondrocyte 
enhancers (Figure 4B). This represents a significant overlap 
of differentially accessible enhancers in knee OA with en-
hancers in MSC-derived chondrocytes (hypergeometric test, 
P < 3.75 × 10−90). This confirms the finding by Lui et al, 
that dysregulated enhancers in OA are enriched in cell-type-
specific enhancers.
3.4 | DNA methylation at gene enhancers
Histone modifications are influenced by DNA methylation 
and vice versa during development.48 DNA methylation 
F I G U R E  3  Clustered similarity heatmap of H3K4me1 and H3K27ac enhancers in hMSC and differentiated chondrocytes vs Roadmap cell 
types. The Jaccard similarity coefficient was calculated between state 13_EnhS in the Transwell chondrogenesis model and 9_EnhA1 in Roadmap 
18 state model across cell types. Both states are characterized by high enrichment of H3K4me1 and H3K27ac. Stem cells and differentiated 
chondrocytes from this study are labeled “hMSC” and “CHON”, respectively. Chondrocytes are indicated by black boxes. A list of Roadmap cell 
types and their ID codes can be found on the Roadmap project website (http://www.roadm apepi genom ics.org)
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occurs at CpG sites in the genome and is typically associ-
ated with transcriptional repression. An Illumina Infinium 
HumanMethylation450K BeadChip array was used to meas-
ure DNA methylation. DNA methylation changes during the 
in vitro Transwell model of chondrogenesis were largely de-
methylation events that were associated with chondrogenesis-
related GO terms.36 We integrated the DNA methylation and 
ChIP-seq data in order to investigate the DNA methylation 
changes in chromatin states during MSC chondrogenesis, fo-
cusing on the hypomethylated CpGs (94% of the significantly 
differentially methylated loci during chondrogenesis) since 
this is linked to gene transcription activation. Global methyl-
ation patterns reflect known trends (Figure 5A,B), for exam-
ple, gene promoters tend to have low percentage methylation 
relative to the rest of the genome.49 We observed that en-
hancers marked by H3K4me1 and H3K27ac (13_EnhS state) 
were enriched for de-methylated CpG sites (Figure 5C,D). 
Fewer than 2% of total CpGs probes present on the Infinium 
HumanMethylation450K BeadChip were located within 
chondrocyte chromatin state 13_EnhS (strong enhancers) yet 
remarkably 41.8% of de-methylated CpGs were found in this 
chromatin state (Figure 5E), a highly significant over-repre-
sentation (Chi-square test P < .001). We evaluated the effect 
of DNA methylation in six selected regions (Table S2) that 
acquired enhancer status during chondrogenesis in both our 
model and the chondrogenesis model in Roadmap and also 
overlapped with a H3K27ac signature during development 
in of human embryonic limbs.50 The nearest gene to each of 
these six regions (ASPSCR1, TLE3, WWP2, ZMIZ1, LRP5, 
and MYEOV) has also been reported to be important in chon-
drogenesis or cartilage-related diseases. CpG sites around the 
ASPSCR1 gene are differentially methylated in human knee 
OA compared to control.51 TLE3 is a target of the SOX5, 
SOX6, and SOX9 trio of transcription factors important in 
chondrogenesis52 and is also involved in osteoblastogen-
esis.53 Wwp2, an E3 ubiquitin ligase, maintains cartilage ho-
meostasis through the regulation of Adamts-5.54 The gene is 
also the host for miR140, which is located toward the 3′ end 
of the WWP2 gene and is co-expressed with an isoform of 
WWP2. MiR140 expression is unique to cartilage and plays 
an essential role in chondrocyte proliferation.23,54-56 ZMIZ1 is 
differentially expressed in OA chondrocytes following expo-
sure to hyperosmotic conditions.57 LRP5 is involved in MSC 
differentiation and cartilage degradation.58,59 MYEOV is as-
sociated with multiple myeloma and may also be involved 
in abnormal bone homeostasis.60 Furthermore, CpG sites 
within these enhancers show a decrease of DNA methylation 
during chondrogenesis (Figure S20). The enhancer regions 
were cloned into a luciferase reporter vector with and with-
out treatment of a CpG methyltransferase. Unmethylated en-
hancer regions showed increased enhancer activity compared 
to the empty vector control, confirming that regions classed 
as enhancers in our model exhibit enhancer activity. With 
the addition of a CpG methyltransferase, all regions showed 
a significant decrease in enhancer activity compared to un-
methylated regions (Figure 5F).
F I G U R E  4  Comparison of shared hMSC-derived chondrocyte enhancers to human articular chondrocyte and H1-derived chondrocyte 
enhancers. A, There were 23 158 shared enhancer regions between differentiated chondrocytes defined in this study and Roadmap E049 enhancers. 
This shared hMSC-derived chondrocyte enhancer signature was more similar to adult articular chondrocytes (dashed red box) compared to fetal 
articular chondrocytes or H1-derived chondrocytes, as determined by the Jaccard similarity index. Jaccard similarity values were converted to 
Euclidean distance for hierarchical clustering. The height of the dendrogram represents the distance between samples; nodes joining at lower 
heights are more similar compared to those joining at greater heights. B, Overlap of shared hMSC-derived chondrocyte enhancers with enhancers 
defined in OA knee cartilage. The proportion of enhancers dysregulated in knee OA is shaded in red. A hypergeometric test shows there was a 
significant overrepresentation of dysregulated enhancers that overlapped with shared hMSC-derived chondrocyte enhancers (P < 3.75 × 10−90)
(A) (B)
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3.5 | Transcription factor binding at 
chondrocyte enhancers
Transcription factor binding occurs at gene enhancers to reg-
ulate gene expression.61,62 Therefore, we determined whether 
chondrocyte enhancers defined in this study contained any 
transcription factor-binding motifs. De novo motif searching 
of the chondrocyte strong enhancer state (13_EnhS) revealed 
SOX9-binding motifs (Figure 6A). Motifs found in the strong 
enhancer state were highly specific to skeletal development 
F I G U R E  5  DNA methylation in chondrocyte chromatin states. A,B, Methylation levels of CpGs in the hMSC and chondrocyte chromatin 
states, respectively. CpG genome coordinates were intersected with chromatin states using BEDTools intersect. C, Empirical cumulative frequency 
plot of methylation changes (beta values) in chondrocyte chromatin states during hMSC chondrogenesis. D, Significantly methylated CpGs 
(FDR < 0.05) in between hMSCs and chondrocytes in chondrocyte chromatin states. E, The percentage of all CpGs on the 450k array in each 
chondrocyte chromatin state and the percentage of de-methylated CpGs during chondrogenesis in chondrocyte chromatin states. F, Luciferase 
reporter assay with enhancer regions with and without DNA methylation (n = 6). Enhancers are labeled with their nearest gene. Significance 
levels: (*) P-value < .05, (**) P-value < .01, and (***) P-value < .001. Error bars are ± standard deviation
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with associations to skeletal diseases. For example, there was 
a positive match to a CREB3L1/OASIS motif, a transcrip-
tion factor involved in the bone formation.63 Mutations in 
CREB3L1 have been linked to osteogenesis imperfecta.64-66 
There was a match to ELF3, a transcription factor impor-
tant during chondrogenesis67 and in cartilage degradation 
in OA.68,69 Other matches include the HES and HEY fam-
ily of transcription factors that are involved in chondrocyte 
hypertrophy during development 70,71 (Table S6). The strong 
promoter state (2_TssS) also contained motifs belonging to 
transcription factors important in chondrogenesis such as 
SOX9 and ELF3 but also matched motifs of general tran-
scription factors such as SP1 and the ETS family of transcrip-
tion factors (Table S7).
SOX9 is a pivotal transcription factor driving chon-
drogenesis and interacts with promoters and enhancers to 
promote chondrogenesis.72 To further characterize chon-
drocyte enhancers, they were classified into two groups: 
new enhancers, defined by a change in chromatin state 
from quiescent or repressed to active enhancers during 
chondrogenesis, and constant enhancers; regions which 
were active enhancers both prior and post chondrogen-
esis. The analysis of motif enrichment (AME) algorithm 
implemented in the MEME suite of motif searching tools 
was used to contrast relative SOX9 motif enrichment in 
these two classes of enhancers found in chondrocytes. We 
found that both SOX9 motifs were significantly more en-
riched in the new enhancer class compared to the constant 
enhancer class (Figure S21). This suggests that enhancers 
have different properties depending on whether they ac-
quired enhancer status upon differentiation or if they were 
enhancers beforehand.
To investigate whether SOX9 binds to motifs found in 
chondrocyte enhancers we used a publicly available mouse 
rib chondrocyte SOX9 ChIP-seq dataset72 and converted the 
data to human genome coordinates. SOX9 is an evolution-
ary conserved transcription factor with conserved binding 
sites.73-75 De novo motif searching using lifted over SOX9 
peaks recovered human SOX9 motifs (Table S7), as was the 
case with the original mouse analysis.72 This is evidence that 
the SOX9 binding site is conserved and the lifted over se-
quences contain SOX9 motifs, rather than being lifted over 
due to regional homology of the sequences around the motif. 
The majority of SOX9 peaks derived from mouse ChIP-
seq data were found in the chondrocyte strong promoter 
(2_TssS) state, strong active enhancer state (13_EnhS) state 
F I G U R E  6  Transcription factor binding in chondrocyte chromatin states. A, Transcription factor motifs found in the chondrocyte strong 
enhancer state. TF motifs found include SOX9, CREB3L1 and ELF3 (Table S6). De novo motif analysis was performed using MEME. B, Numbers 
of SOX9 peaks derived from mouse rib chondrocyte ChIP-seq data in chondrocyte chromatin states. Jaccard index of similarity between SOX9 
peaks and chondrocyte chromatin states. C, Luciferase reporter assay with enhancer regions ± SOX9 overexpression (n = 6). Enhancers are 
labeled with their nearest gene. 4COL is a luciferase reporter containing four copies of the Col2a1 48-bp enhancer and was used to confirm SOX9 
overexpression27 Significance levels: (**) P-value < .01 and (***) P-value < .001. Error bars are ± standard deviation
(A)
(C)(B)
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and quiescent state (16_Quies); the latter simply being due 
to the high percentage of the genome marked quiescent. 
Accounting for the size of chromatin states, there was more 
SOX9 enrichment in promoter and enhancer states (Figure 
6B). This confirms that the chondrocyte promoters and en-
hancers identified in our study contain real and conserved 
SOX9-binding sites. The impact of SOX9 overexpression 
was assessed on the previously cloned enhancer regions and 
a SOX9-responsive Col2a1 enhancer reporter27 (Figure 6F). 
Four out of six enhancers exhibited increased enhancer ac-
tivity with SOX9 overexpression (Figure 6C). All regions 
except one (nearest gene TLE3) have a SOX9-binding site in 
the lifted over SOX9 ChIP-seq data; as predicted, the TLE3 
region did not show increased enhancer activity upon SOX9 
overexpression.
Previously, analysis of mouse Sox9 ChIP-seq found that 
AP-1 factors, Jun, and Fos were found to co-localize with 
Sox9.72,76 The authors found that whilst Sox9 and AP-1 
factors can form protein-protein complexes, co-localiza-
tion primarily occurred through the binding of factors to 
the same binding sites. Positive matches to JUN and FOS 
motifs were also found in the de novo motif search of lifted 
over SOX9 peaks (Table S8), demonstrating that this mech-
anism is conserved between the two species.
4 |  DISCUSSION
There are numerous in vitro models of chondrogenesis and 
although some models utilize scaffolds for cells to grow, 
scaffold-free models are reported to better reflect the con-
ditions during in vivo chondrogenesis during develop-
ment.77 Chondrocytes from this study were derived from 
a scaffold-free chondrogenesis model using bone marrow-
derived hMSCs. Other scaffold-free models include the 
micromass and pellet culture system. In contrast, chondro-
cytes from the Roadmap project were derived from human 
BM-MSCs in a 3D alginate chondrogenesis model.10 Whilst 
there has been some gene expression comparisons between 
models,78,79 no comparison has been made about changes 
in their epigenetic landscape. Here, we show that chondro-
cyte gene enhancers across two different models are highly 
concordant relative to other cell-types. This is indicative 
of a unique chondrocyte epigenetic signature, independent 
of model and laboratory-specific effects. Although hMSC-
derived chondrocyte enhancer concordance is evidence 
that chondrogenic models are reliable and comparable, fur-
ther work is required to establish their likeness to in vivo 
chondrocytes. We observed both articular and growth plate 
chondrocyte gene expression markers in our differenti-
ated chondrocytes. However, although the classical gene 
for hypertrophy, COL10A1, is upregulated, protein pro-
duction or matrix deposition appears to be limited.21,39 An 
upregulation of markers of hypertrophy is also commonly 
observed in pellet models of hMSC chondrogenesis.80-82 
More work is needed to determine whether in vitro sys-
tems reflect chondrocytes which undergo endochondral os-
sification or articular chondrocytes found in adult synovial 
joints. However, we have identified in vitro chondrocyte 
enhancers that overlap with enhancers found in knee car-
tilage and corroborated that enhancers dysregulated in OA 
are more likely to be cell-type-specific enhancers.47 The 
concordance between enhancers identified between hMSC 
chondrogenesis models and OA suggests that in vitro mod-
els have an important role in studies into cartilage develop-
ment and disease.
Combinations of histone modifications can define reg-
ulatory elements and regulate genes through modulating 
chromatin remodeling to allow or block access to transcrip-
tion factors. However, histone modifications also rely on 
other epigenetic mechanisms such as DNA methylation and 
vice versa.48 Crosstalk between the two epigenetic mecha-
nisms allows for greater control of gene transcription and it 
is important to consider histone modifications in the wider 
context of the whole epigenome. Traditionally, studies 
into DNA methylation focused on gene promoters where 
CpG islands are more likely to be found and array probe 
design is biased toward promoters. Although our data are 
extensive, we only compared ~ 450,000 (1.6%) of the ~28 
million CpG sites in the human genome.83 Reduced repre-
sentation bisulfite sequencing (RRBS) in chondrogenesis 
only identified limited CpG methylation changes in gene 
promoters.10 However, RRBS is heavily biased toward pro-
moters and whole-genome bisulfite sequencing remains the 
only method that can universally capture almost the entire 
DNA methylome. We show in this study that significant 
changes occur at distal gene enhancers during chondrogen-
esis. DNA demethylation at enhancer regions has also been 
observed during other stem cell differentiation processes, 
including differentiation of intestinal epithelium progen-
itors,84 hematopoietic stem cells 85 and embryonic stem 
cells 86 but also due to MSC age and culture conditions.87 
DNA demethylation at enhancers is associated with the de-
velopment of most human organs.88 Aberrant DNA methyl-
ation in enhancers has been implicated in diseases such as 
cancer89-91 and osteoarthritis (OA).51,92
Motif discovery at chondrocyte enhancers recovered 
motifs of transcription factors known to be involved in car-
tilage development and diseases such as CREB3L1, ELF3, 
and SOX9. We utilized a mouse Sox9 ChIP-seq dataset to 
assess whether enhancers defined in our study contained 
SOX9-binding sites. SOX9 has a highly conserved DNA-
binding motif and function.93-96 Therefore, we considered 
the liftover of mouse reads to human genome coordinates 
to be appropriate for our analysis. Indeed, we recovered 
a human SOX9 motif from lifted over peaks, illustrating 
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that the DNA-binding sites and motif of SOX9 are highly 
conserved between human and mouse. Using liftover, spe-
cies-specific SOX9-binding information is lost but con-
served sites are retained, these sites arguably being the 
most important, as evolutionary conservation is a marker 
of essentiality. We found SOX9 motifs in our chondrocyte 
enhancers via de novo motif searching as well as conserved 
SOX9 binding using mouse SOX9 ChIP-seq. SOX9 acts 
in conjunction with transcription factors SOX5 and SOX6 
in chondrogenesis,97 to bind to super enhancers promoting 
chondrogenesis.98 Super enhancers are loosely defined as 
multiple enhancers in close proximity exhibiting high levels 
of active enhancer markers such as H3K27ac or transcrip-
tion factors (Pott and Lieb, 2015). SOX9 bound enhancers 
have previously been proposed to be important for defin-
ing the chondrocyte phenotype. Furthermore, mutations 
of Sox9-binding motifs within distal Acan enhancers in 
transgenic mice resulted in a loss of chondrocyte-specific 
expression.99
Enhancers are thought to regulate their target genes by 
forming a loop to physically contact the gene promoter within 
topologically associating domains100,101; an interaction me-
diated by transcription factors.102 Gene enhancers can be lo-
cated distal from their target promoters and therefore, target 
gene prediction can be challenging without chromatin con-
formation data.103 Although we have validated that enhancers 
identified in this study do, indeed, possess enhancer activ-
ity that may be modulated by DNA methylation and SOX9 
binding, further functional work is required to elucidate their 
gene target(s) and importance in cartilage development. In 
this study, we show that enhancers are dynamic during chon-
drogenesis and may serve as potential targets for modulating 
hMSC differentiation.
To conclude, the integration of ChIP-seq with methylation 
data revealed that gene enhancers are de-methylated during an 
in vitro Transwell model of chondrogenesis. Comparison of 
chromatin states across hMSCs and chondrocytes generated 
in this study along with those from the Roadmap Epigenomics 
project revealed that enhancers marked by H3K4me1 and 
H3K27ac are more cell-type specific compared to other chro-
matin states. Chondrocytes from the Epigenomics Roadmap 
project and this study showed a more similarity of en-
hancers with each other than other cell-types despite being 
from different models. We have established that chondro-
cyte enhancers contain motifs to which SOX9 binds in vivo. 
Additional investigations are needed to elucidate further the 
epigenetic landscape of chondrocytes originating from other 
in vitro models and to determine whether these are compara-
ble to the epigenome of human articular chondrocytes. A link 
between reactivation of developmental pathways and OA has 
been suggested17; more research is needed to fully explore the 
association between development and disease.
5 |  CONCLUSION
Human mesenchymal stem cells are able to differentiate 
into chondrocytes, the cell type found in cartilage, making 
them an accessible system to study gene regulation during 
this process. Epigenetic mechanisms such as histone modi-
fications and DNA methylation together with transcription 
factor binding play a role in activating and repressing gene 
expression. In this study, we investigated the genome-wide 
histone modification changes during chondrocyte differen-
tiation. Integration of this data with DNA methylation and 
SOX9 transcription factor ChIP-seq revealed epigenetic 
changes at gene enhancer elements. Regions of the genome 
that transition from non-enhancers to enhancers in chondro-
cytes are enriched for SOX9 transcription factor-binding 
sites. Luciferase reporter assays revealed that enhancer activ-
ity may be modulated by manipulating DNA methylation and 
SOX9 expression. This study has defined important regula-
tory elements in chondrocytes which could serve as targets 
for future mechanistic studies.
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